Open AccessPharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
Author(s) -
Eric H. Decloedt,
Phumla Sinxadi,
Lubbe Wiesner,
John A. Joska,
David W. Haas,
Gary Maartens
Publication year - 2021
Publication title -
southern african journal of hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.859
H-Index - 18
eISSN - 2078-6751
pISSN - 1608-9693
DOI - 10.4102/sajhivmed.v22i1.1206
Subject(s) - emtricitabine , efavirenz , medicine , cerebrospinal fluid , pharmacology , pharmacokinetics , slco1b1 , tenofovir , pharmacogenetics , genotype , virology , human immunodeficiency virus (hiv) , antiretroviral therapy , biology , genetics , viral load , gene
Background Blood-cerebrospinal fluid (CSF) barrier transporters affect the influx and efflux of drugs. The antiretrovirals tenofovir and emtricitabine may be substrates of blood-brain barrier (BBB) and blood-CSF barrier transporters, but data are limited regarding the pharmacogenetics and pharmacokinetics of their central nervous system (CNS) penetration. Objectives We investigated genetic polymorphisms associated with CSF disposition of tenofovir and emtricitabine. Method We collected paired plasma and CSF samples from 47 HIV-positive black South African adults who were virologically suppressed on efavirenz, tenofovir and emtricitabine. We considered 1846 single-nucleotide polymorphisms from seven relevant transporter genes ( ABCC5, ABCG2, ABCB1, SLCO2B1, SCLO1A2, SLCO1B1 and ABCC4 ) and 782 met a linkage disequilibrium (LD)-pruning threshold. Results The geometric mean (95% confidence interval [CI]) values for tenofovir and emtricitabine CSF-to-plasma concentration ratios were 0.023 (0.021–0.026) and 0.528 (0.460–0.605), respectively. In linear regression models, the lowest p -value for association with the tenofovir CSF-to-plasma ratio was ABCB1 rs1989830 ( p = 1.2 × 10 −3 ) and for emtricitabine, it was ABCC5 rs11921035 ( p = 1.4 × 10 −3 ). None withstood correction for multiple testing. Conclusion No genetic polymorphisms were associated with plasma, CSF concentrations or CSF-to-plasma ratios for either tenofovir or emtricitabine.